載入中
NASDAQHealthcareBiotechnology
最新資料
US$16.55
−US$0.44 · -2.59%
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
收盤時
US$16.55
−US$0.44 · -2.59%
盤後
US$13.5075
−US$3.0425 · -18.38%
10月12日 下午7:59 ET
盤中時間採用ET。市場資料可能有所延遲。
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
日內區間
目前US$16.55
52週區間
目前US$16.55
盤中時間採用ET。市場資料可能有所延遲。
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
日內區間
目前US$16.55
52週區間
目前US$16.55
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.72億 USD | 2368萬 USD | — | — | 1.4億 USD |
| 銷貨成本 | 697萬 USD | 82.6萬 USD | — | — | — |
| 毛利 | 1.65億 USD | 2285.4萬 USD | — | — | 1.4億 USD |
| 研究與開發 | 2.59億 USD | 2.42億 USD | 1.63億 USD | 1.18億 USD | 8824.8萬 USD |
| 銷售、一般及管理費用 | 1.8億 USD | 1.21億 USD | 6692.2萬 USD | 3325.8萬 USD | 2524.1萬 USD |
| 營業費用 | 4.38億 USD | 3.63億 USD | 2.3億 USD | 1.52億 USD | 1.13億 USD |
| 利息收入 | 2273萬 USD | 2609萬 USD | 2116.3萬 USD | 587.2萬 USD | 40.3萬 USD |
| 利息支出 | 3378.5萬 USD | 492.9萬 USD | 20.8萬 USD | 313.7萬 USD | 189.9萬 USD |
| 折舊和攤銷 | 6000 USD | 8000 USD | 1.2萬 USD | 3.3萬 USD | 4.3萬 USD |
| 營業利益 | −2.73億 USD | −3.4億 USD | −2.3億 USD | −1.52億 USD | 2622萬 USD |
| 淨利 | −2.85億 USD | −3.19億 USD | −2.09億 USD | −1.49億 USD | 2492.6萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$36.67
上漲空間 121.57%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI5468.17萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI4260.96萬0.43%103.03億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM3933.94萬0.05%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF1989.04萬0.02%954億 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1394.85萬0.10%139.17億 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB1077萬0.10%108.2億 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO987.37萬0.05%180億 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA802.34萬0.04%218.24億 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
